We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report.
- Authors
Wu, Yining; Ou, Shenjian; Liao, Xiwen; Han, Chuangye; Yang, Chengkun; Qin, Wei; Tan, Yufeng; Lao, Quan; Peng, Tao; Ye, Xinping
- Abstract
Situs inversus totalis (SIT) is a rare congenital condition in which abdominal and thoracic organs are transposed from normal positions. Two-stage hepatectomy (TSH) combined with translational therapy for hepatocellular carcinoma (HCC) with SIT has been rarely reported. We report a 41-year-old man with giant hepatocellular carcinoma (71 mm × 55 mm × 51 mm) whose future residual liver (FLR) and standard liver volume (SLV) ratio at first diagnosis was 37.4%. Preoperative volume assessment of portal vein ligation (PVL) revealed inadequate hypertrophy of FLR. After a multidisciplinary group discussion (MDT), the patient decided to follow conversion therapy. Three months later, ratio of the FLR/SLV increased from 37.4% to 71% after operation, which met the surgical requirements. Second hepatectomy, right lobectomy was successful. There was no recurrence after six months of follow-up. In our case, conversion therapy appears to be effective in maintaining residual liver hyperplasia, reducing tumor load, and preventing tumor progression in patients with large HCC during TSH.
- Publication
Pharmacogenomics & Personalized Medicine, 2023, Vol 16, p111
- ISSN
1178-7066
- Publication type
Article
- DOI
10.2147/PGPM.S376596